TARO-POSACONAZOLE DIN 02543311
Health Canada record
| Active ingredient(s) | POSACONAZOLE 100 MG |
|---|---|
| Dosage form | Tablet (Delayed-Release) |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | J02AC04 POSACONAZOLE |
| Original market date | 25-Mar-2024 |
| Current status date | 25-Mar-2024 |
| Source | Health Canada DPD |
Establishment licence of the holder
Taro Pharmaceuticals Inc — licence 100232, not currently licensed, last inspection rating C (2025-03-24).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing POSACONAZOLE
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02511878 | APO-POSACONAZOLE | APOTEX INC | Tablet (Delayed-Release) | POSACONAZOLE 100 MG | Approved |
| 02542021 | GLN-POSACONAZOLE | GLENMARK PHARMACEUTICALS CANADA INC. | Tablet (Delayed-Release) | POSACONAZOLE 100 MG | Marketed |
| 02530333 | JAMP POSACONAZOLE | JAMP PHARMA CORPORATION | Suspension | POSACONAZOLE 40 MG | Marketed |
| 02544644 | MINT-POSACONAZOLE | MINT PHARMACEUTICALS INC | Tablet (Delayed-Release) | POSACONAZOLE 100 MG | Marketed |
| 02432676 | POSANOL | MERCK CANADA INC | Solution | POSACONAZOLE 300 MG | Marketed |
| 02424622 | POSANOL | MERCK CANADA INC | Tablet (Delayed-Release) | POSACONAZOLE 100 MG | Marketed |
| 02293404 | POSANOL | MERCK CANADA INC | Suspension | POSACONAZOLE 200 MG | Marketed |
| 02496259 | SANDOZ POSACONAZOLE | SANDOZ CANADA INCORPORATED | Tablet (Delayed-Release) | POSACONAZOLE 100 MG | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 32201 | 2023-11-29 | Abbreviated New Drug Submission (ANDS) |
International API supply for POSACONAZOLE
33 active FDA Drug Master Files.
Request a quote for TARO-POSACONAZOLE